Skip to main content
. Author manuscript; available in PMC: 2018 Apr 3.
Published in final edited form as: Thromb Haemost. 2017 Jan 26;117(4):671–681. doi: 10.1160/TH16-09-0691

Figure 7. Activation of fXI and PK anion-binding site (ABS) variants in the presence of nucleic acids.

Figure 7

Recombinant fXI species (30 nM) were incubated without (□,○,∆) or with (■,●,▲) (A) 5 μg/ml DNA or (B) 1 μg/ml RNA, and with 2.5 nM thrombin (left) or 2.5 nM fXIIa (right). Symbols: fXI-WT (□,■), fXI-ABS1 (○,●), or fXI-ABS2 (∆,▲). (C) FXI-ABS2 (30 nM) was incubated with 5 μg/ml DNA and 2.5 nM thrombin (left) or 2.5 nM fXIIa (right) without (○) or with (●) 30 nM HK. (D) 60 nM PK-WT (left) or PK-ABS2 (right) were incubated with 50 pM fXIIa in the presence of 5 μg/ml DNA without (○) or with (●) 60 nM HK. For all reactions, at indicated time points, aliquots were tested for fXIa or kallikrein activity by chromogenic assay. Error bars are +/−one SD.